Clinical trial
Efficacy of Rostafuroxin in the Treatment of Essential Hypertension
NCT00415038 · sigma-tau i.f.r. S.p.A., Industry · Completed
Key facts
| NCT number | NCT00415038 |
|---|---|
| Title | Efficacy of Rostafuroxin in the Treatment of Essential Hypertension |
| Official title | A Double Blind, Dose Range, Placebo Controlled Study of the Effects of Rostafuroxin vs Placebo in Patients With Stable, Uncomplicated, Essential Hypertension. |
| Lead sponsor | sigma-tau i.f.r. S.p.A., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Essential Hypertension |
| Intervention type | Drug |
| Interventions | Rostafuroxin |
| Enrollment | 438 |
| Start date | Feb 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Dec 22, 2006 |
| Last update posted | Jun 17, 2011 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: